Several studies suggest that atherosclerotic disease is not a focal disease restricted to culprit lesions in the intima of the arterial wall, but seems to act as a general disease affecting the entire cardiovascular system. Evolving research has lately focused on the atherosclerotic component in calcific aortic stenosis (AS) as it seems that the valve is affected in a pattern similar to that of the vasculature. The hope is therefore, that we someday in the management of patients with calcific AS can apply some of the same treatment strategies as in atherosclerotic vascular disease. This article reviews the pathophysiological mechanisms of calcific AS, reviews current clinical trials of statin use in aortic stenosis and reports on on-going trials, evaluating whether cholesterol lowering therapy can slow disease progression in different populations. Finally, we review if computerized tomography, biomarkers, and clinical characteristics such as left ventricular ejection fraction, can be useful in stratifying patients to potential benefit of statin therapy.
Antonini-Canterin, F., Popescu, B.A., Huang, G., Korcova-Miertusova, R., Rivaben, D., Faggiano, P. et al. (2005) Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J6: 119-124.
2.
Blankenberg, S., Barbaux, S. and Tiret, L. (2003) Adhesion molecules and atherosclerosis. Atherosclerosis170: 191-203.
3.
Bonow, R.O., Carabello, B.A., Kanu, C., de Jr, L.A., Faxon, D.P., Freed, M.D. et al. (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation114: e84-231.
4.
Chan, K.L. (2003) Is aortic stenosis a preventable disease? J Am Coll Cardiol42: 593-599.
5.
Chan, K.L. and Teo, K. (2005) Lipid-lowering therapy in calcific aortic stenosis . N Engl J Med353: 1066-1067.
6.
Chan, K.L., Teo, K., Tam, J. and Dumesnil, J.G. (2007) Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J153: 925-931.
7.
Cote, C., Pibarot, P., Despres, J.P., Mohty, D., Cartier, A., Arsenault, B. et al. (2007) Association between circulating oxidized low-density lipoprotein and fibro-calcific remodeling of the aortic valve in aortic stenosis. Heart published online doi:10.1136/hrt.2007.125740.
8.
Cowell, S.J., Newby, D.E., Prescott, R.J., Bloomfield, P., Reid, J., Northridge, D.B. et al. (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med352: 2389-2397.
9.
Dawkins, S., Hobson, A.R., Kalra, P.R., Tang, A.T., Monro, J.L. and Dawkins, K.D. (2008) Permanent pacemaker implantation after isolated aortic valve replacement: incidence, indications, and predictors. Ann Thorac Surg85: 108-112.
10.
de Boer, O.J., van der Wal, A.C., Teeling, P. and Becker, A.E. (1999) Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization?Cardiovasc Res41: 443-449.
11.
Eckel, R.H., Grundy, S.M. and Zimmet, P.Z. (2005) The metabolic syndrome. Lancet365: 1415-1428.
12.
Freeman, R.V., Crittenden, G. and Otto, C. (2004) Acquired aortic stenosis. Expert Rev Cardiovasc Ther2: 107-116.
13.
Freeman, R.V. and Otto, C.M. (2005) Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation111: 3316-3326.
Griffin, B.P. (2007) The effect of lipitor in aortic stenosis. http://clinicaltrials.gov/ct2/show/NCT00590135ID:NCT00590135 .
16.
Iivanainen, A.M., Lindroos, M., Tilvis, R., Heikkila, J. and Kupari, M. (1996) Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol78: 97-101.
17.
Katz, R., Wong, N.D., Kronmal, R., Takasu, J., Shavelle, D.M., Probstfield, J.L. et al. (2006) Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation113: 2113-2119.
18.
Kizu, A., Shioi, A., Jono, S., Koyama, H., Okuno, Y. and Nishizawa, Y. (2004) Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem93: 1011-1019.
19.
Kuiper, J., van Puijvelde, G.H., van Wanrooij, E.J., van Es, T., Habets, K., Hauer, A.D. et al. (2007) Immunomodulation of the inflammatory response in atherosclerosis . Curr Opin Lipidol18: 521-526.
20.
Laissy, J.P., Messika-Zeitoun, D., Serfaty, J.M., Sebban, V., Schouman-Claeys, E., Iung, B. et al. (2007) Comprehensive evaluation of preoperative patients with aortic valve stenosis: usefulness of cardiac multidetector computed tomography. Heart93: 1121-1125.
21.
Lester, S.J., Heilbron, B., Gin, K., Dodek, A. and Jue, J. (1998) The natural history and rate of progression of aortic stenosis. Chest113: 1109-1114.
22.
Lindroos, M., Kupari, M., Heikkila, J. and Tilvis, R. (1993) Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol21: 1220-1225.
23.
Martinez, M.W. and Nishimura, R.A. (2006) Approach to the patient with aortic stenosis and low ejection fraction. Curr Cardiol Rep8: 90-95.
24.
Mays, M.E. and Dujovne, C.A. (2008) Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia? Curr Atheroscler Rep10: 45-52.
25.
Mazzone, A., Epistolato, M.C., Gianetti, J., Castagnini, M., Sassi, C., Ceravolo, R. et al. (2006) Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol126: 494-502.
26.
Messika-Zeitoun, D., Aubry, M.C., Detaint, D., Bielak, L.F., Peyser, P.A., Sheedy, P.F. et al. (2004) Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation110: 356-362.
27.
Mohler, E.R., III. (2004) Mechanisms of aortic valve calcification. Am J Cardiol94: 1396-1402, A6.
28.
Mohler, E.R., III, Medenilla, E., Wang , H. and Scott, C. (2006) Aortic valve calcium content does not predict aortic valve area. J Heart Valve Dis15: 322-328.
29.
Mohler, E.R., III, Wang, H., Medenilla, E. and Scott, C. (2007) Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis16: 378-386.
30.
Mohty, D., Pibarot, P., Despres, J.P., Cote, C., Arsenault, B., Cartier, A. et al. (2008) Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol28: 187-193.
31.
Moura, L.M., Ramos, S.F., Zamorano, J.L., Barros, I.M., Azevedo, L.F., Rocha-Goncalves, F. et al. (2007) Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol49: 554-561.
32.
Nordestgaard, B.G. and Nielsen, L.B. (1994) Atherosclerosis and arterial influx of lipoproteins . Curr Opin Lipidol5: 252-257.
33.
Novaro, G.M., Katz, R., Aviles, R.J., Gottdiener, J.S., Cushman, M., Psaty, B.M. et al. (2007) Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol50: 1992-1998.
34.
O'Brien, K.D. (2006) Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol26: 1721-1728.
35.
O'Brien, K.D., Reichenbach, D.D., Marcovina, S.M., Kuusisto, J., Alpers, C.E. and Otto, C.M. (1996) Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of `degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol16: 523-532.
36.
O'Regan, C., Wu, P., Arora, P., Perri, D. and Mills, E.J. (2008) Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med121: 24-33.
37.
Otto, C.M., Burwash, I.G., Legget, M.E., Munt, B.I., Fujioka, M., Healy, N.L. et al. (1997) Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome . Circulation95: 2262-2270.
38.
Otto, C.M., Kuusisto, J., Reichenbach, D.D., Gown, A.M. and O'Brien, K.D. (1994) Characterization of the early lesion of `degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation90: 844-853.
39.
Pellikka, P.A., Sarano, M.E., Nishimura, R.A., Malouf, J.F., Bailey, K.R., Scott, C.G. et al. (2005) Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation111: 3290-3295.
40.
Rajamannan, N.M., Bonow, R.O. and Rahimtoola, S.H. (2007) Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med4: 254-262.
41.
Rajamannan, N.M., Subramaniam, M., Caira, F., Stock, S.R. and Spelsberg, T.C. (2005) Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation112: 1229-1234.
42.
Rizzo, M. and Berneis, K. (2006) The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther20: 205-217.
43.
Rosenhek, R., Binder, T., Porenta, G., Lang, I., Christ, G., Schemper, M. et al. (2000) Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med343: 611-617.
44.
Ross Jr, J. and Braunwald, E. (1968) Aortic stenosis. Circulation38: 61-67.
45.
Rossebo, A.B., Pedersen, T.R., Allen, C., Boman, K., Chambers, J., Egstrup, K. et al. (2007) Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol99: 970-973.
46.
Sanchez, P.L. (2006) Randomized study to evaluate the efficacy of fluvastatin on inflammatory markers in patients with aortic stenosis. http://clinicaltrials.gov/ct2/show/NCT00590135ID:NCT00590135.
47.
Sanchez, P.L., Santos, J.L., Kaski, J.C., Cruz, I., Arribas, A., Villacorta, E. et al. (2006) Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol97: 90-93.
48.
Schuler, G. (2005) Statin therapy in asymptomatic aortic stenosis . http://clinicaltrials.gov/ct2/show/NCT00176410ID:NCT00176410.
49.
Selwyn, A.P. (2007) Antiatherosclerotic effects of statins: LDL versus non-LDL effects. Curr Atheroscler Rep9: 281-285.
50.
Shively, B.K., Charlton, G.A., Crawford, M.H., Chaney, R.K. (1998) Flow dependence of valve area in aortic stenosis: relation to valve morphology. J Am Coll Cardiol31: 654-660.
51.
St Pierre, A.C., Cantin, B., Dagenais, G.R., Mauriege, P., Bernard, P.M., Despres, J.P. et al. (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol25: 553-559.
52.
Stewart, B.F., Siscovick, D., Lind, B.K., Gardin, J.M., Gottdiener, J.S., Smith, V.E. et al. (1997) Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J AmColl Cardiol29: 630-634.
53.
Tabas, I., Williams, K.J. and Boren, J. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation116: 1832-1844.
54.
Ward, S., Lloyd, J.M., Pandor, A., Holmes, M., Ara, R., Ryan, A. et al. (2007) A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess11: 1-iv.
55.
Warren, B.A. andYong, J.L. (1997) Calcification of the aortic valve: its progression and grading. Pathology29: 360-368.
56.
Weber, M., Hausen, M., Arnold, R., Nef, H., Moellman, H. and Berkowitsch, A. et al. (2006) Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart92: 1639-1644.
57.
Wen, Y. and Leake, D.S. (2007) Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ Res100: 1337-1343.
58.
Williams, K.J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis . Arterioscler Thromb Vasc Biol15: 551-561.
